Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Minerva Neurosciences, Inc - Common Stock (NQ:NERV)

6.410 +3.750 (+140.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Minerva Neurosciences, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Earnings Scheduled For March 8, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. 
Via Benzinga
Earnings Preview For Minerva Neurosciences
 
Via Benzinga
Minerva Neurosciences Shares Sink On Regulatory Setback For Schizophrenia Candidate
 
Via Benzinga
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
Management to Host Conference Call 
From Minerva Neurosciences, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
EXCLUSIVE: The Benzinga Moneymaker Series, 5 Emerging Stocks For Investors To Watch
Investors are on the hunt for undervalued, underfollowed and emerging stocks to spot opportunities. The rise of social media and retail traders gave way to countless methods to uncover new information.... 
Via Benzinga
Tesla, Amazon, Minerva, Kala Pharma, Gorilla Tech: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed in the red on Wednesday as investors and traders lost optimism regarding any possible year-end rebound and braced themselves for the new year while lightening up on... 
Via Benzinga
Nasdaq Down 100 Points; Kala Pharmaceuticals Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 100 points on Wednesday. 
Via Benzinga
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Dow Tumbles 150 Points; Crude Oil Falls Sharply
U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 150 points on Wednesday. 
Via Benzinga
US Stocks Rise; Dow Gains 100 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Wednesday. 
Via Benzinga
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Retirement
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022
Upgrades 
Via Benzinga
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
Company To Host Live Webcast Today at 8:30 a.m. ET 
From Minerva Neurosciences, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Merrimack Pharmaceuticals (NASDAQ:MACK) shares rose 180.0% to $11.2 during Wednesday's pre-market session. The company's market cap stands at $150.1 million. As per the news, the Q3 earnings... 
Via Benzinga
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
From Minerva Neurosciences, Inc
Via GlobeNewswire
Why IBM Shares Are Trading Higher; Here Are 21 Stocks Moving Premarket
Gainers COMSovereign Holding Corp. (NASDAQ: COMS) rose 20.9% to $0.1063 in pre-market trading after dipping 26% on Wednesday. COMSovereign recently announced receipt of Nasdaq listing determination. 
Via Benzinga
Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday
Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case. 
Via Benzinga
Dow Rises Over 2%; S&P 500 Up 100 Points
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 300 points on Monday. 
Via Benzinga
Virgin Orbit And 4 More Short Squeeze Stocks That Could Soar This Week — Including A Stock Moving Up 968 Positions
Potential short squeeze plays gained steam in 2021 and has continued through 2022 with new traders looking for the next huge move. Here’s a look at the top five short squeeze candidates based on the... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Nasdaq Jumps 300 Points; Bank of America Tops Q3 Estimates
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 300 points on Monday. 
Via Benzinga
Why Bank of America Shares Are Trading Higher? Here Are 66 Stocks Moving In Monday's Mid-Day Session
Gainers FedNat Holding Company (NASDAQ: FNHC) shares rose 78.9% to $0.93 after jumping 48% on Friday. 
Via Benzinga
GLSI, AVTE: The Top 5 Short Squeeze Stocks to Watch This Week
Short-squeeze stocks continue to be a big deal for speculative traders and we're helping them out with a list to keep in mind this week! 
Via InvestorPlace
Looking Into Minerva Neurosciences's Recent Short Interest
Minerva Neurosciences's (NASDAQ:NERV) short percent of float has fallen 47.4% since its last report. The company recently reported that it has 573 thousand shares sold short, which is 14.49% of all... 
Via Benzinga
US Stocks Open Higher; Dow Surges 500 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 500 points on Monday. 
Via Benzinga
Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.